Parabilis Medicines Q3 Loss Widens to $44.5M on Zolucatetide Push

Parabilis Medicines (Nasdaq: PBLS) reported a third-quarter 2026 net loss of $44.5 million on November 12, 2026, compared with a $33.5 million loss a year earlier, as research and development spending climbed to $45.6 million from $28.2 million. The clinical-stage biotech ended the quarter with $1.1 billion in cash, cash equivalents and marketable securities, up from $27.7 million at December 31, 2025, and said that balance funds operations into 2030.

Context — why Parabilis's cash runway and Phase 3 timing matter now

The company's lead candidate, zolucatetide, is described as the first and only direct inhibitor of the β-catenin:TCF interaction, a node in the Wnt/β-catenin pathway. Parabilis said it reached alignment with the U.S. Food and Drug Administration on dose, regimen and trial design for a Phase 3 registrational study in desmoid tumors, which it plans to call PEDESTAL.

That regulatory alignment is the pivot of the quarter. Without agreed endpoints and dosing, a registrational trial cannot start; with them, the company moves from dose-finding into a randomized, double-blind design. Parabilis said it plans to initiate PEDESTAL in the first half of 2027 and expects topline results in 2029.

The comparable the company itself supplies is the prior-year quarter, when R&D ran at $28.2 million and general and administrative costs at $6.6 million. Both lines rose, and the company attributed the increases to clinical development of zolucatetide across multiple indications plus hiring.

Revenue appeared for the first time in the comparison. Parabilis booked $2.1 million of collaboration revenue in the quarter, against none in the year-earlier period, split between $671,000 of collaboration revenue and $1.4 million from a related party.

The balance sheet changed character, not just size. Convertible preferred stock of $509.97 million at December 31, 2025, fell to zero, while additional paid-in capital rose to $1.69 billion from $15.0 million — the signature of a preferred-to-common conversion tied to a listing. Total stockholders' equity swung to $1.0 billion from a $526.5 million deficit.

Data — what the numbers show

The quarter's financials, all from the company's condensed consolidated statements:

Metric	Q3 2026	Q3 2025
Total revenue	$2.1M	$0
R&D expenses	$45.6M	$28.2M
G&A expenses	$11.3M	$6.6M
Loss from operations	$54.7M	$34.8M
Net loss	$44.5M	$33.5M
Interest income	$10.4M	$0.7M

Interest income of $10.4 million absorbed part of the operating loss, reflecting the enlarged securities portfolio. Nine-month R&D reached $122.7 million against $92.2 million in the prior-year period, and the nine-month net loss widened to a level implied by the reported components.

On the clinical side, Parabilis reported a 72.2% objective response rate, or 13 of 18 patients, at a 32-week landmark among those receiving a starting dose of at least 450 mg in its ongoing Phase 1/2 desmoid tumor trial, from a June 22, 2026, data cut. It reported a 100% disease control rate with no disease progression across all 46 response-evaluable patients at that dose threshold, and a safety profile now shown in 76 patients with no treatment discontinuations due to treatment-related adverse events.

Cash composition matters as much as the headline. Of the $1.1 billion total, $521.2 million sat in cash and cash equivalents, $350.4 million in current marketable securities and $201.3 million in non-current marketable securities. Total assets were $1.13 billion against $126.9 million of total liabilities.

Analysis — what it means for biotech investors and peers

For a clinical-stage oncology name, the relevant question is not the quarterly loss but the ratio of spend to runway. Parabilis burned roughly $57 million of operating expense in a quarter while holding $1.1 billion — a structure that lets it fund a global Phase 3 without returning to markets soon, assuming spending stays near current levels.

The company is also widening zolucatetide's label ambitions beyond desmoid tumors. It initiated a dose-ranging cohort in familial adenomatous polyposis, or FAP, started a Phase 1/2 trial in China to support Chinese enrollment in PEDESTAL, and entered a clinical collaboration with Revolution Medicines to test zolucatetide with zoldonrasib and cetuximab in previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer. Parabilis will sponsor the study; Revolution Medicines supplies zoldonrasib and splits trial costs equally.

The counter-argument is timing. PEDESTAL topline is guided to 2029, and the desmoid response data come from a small landmark cohort of 18 evaluable patients, not a randomized comparison. Single-arm response rates in rare tumors can shift as enrollment broadens, and the company did not disclose the financial terms of the Revolution Medicines collaboration or the size of the FAP cohort.

Positioning follows the calendar. Investors holding PBLS are underwriting a 2027 trial start and a 2029 readout; the near-term flow will be driven by the ESMO and CTOS data presentations and the first-quarter 2027 FAP disclosures rather than by quarterly earnings.

Outlook — what to watch next

Three catalysts sit on the company's own schedule. Parabilis said it will present the June 22, 2026, data cut orally at the Connective Tissue Oncology Society annual meeting in November 2026. It guided to translational data showing on-target activity in FAP, plus clinical data from additional FAP patients, in the first quarter of 2027. It also expects updated clinical data from additional adamantinomatous craniopharyngioma patients in the first half of 2027, and additional hepatocellular carcinoma data at a medical meeting in the first quarter of 2027.

Management appearances give the next near-term checkpoints: Mathai Mammen, chairman, CEO and president, presents at the Jefferies Global Healthcare Conference in London on November 16, 2026, and joins a fireside chat at the Evercore ISI 9th Annual Healthcare Conference on November 30, 2026.

The company did not provide a specific PEDESTAL start date beyond the first half of 2027, and it did not quantify enrollment targets or trial cost. Investors tracking the name should watch for any revision to the 2030 cash runway guidance, which is the clearest signal of whether the Phase 3 build-out stays inside the current spending envelope.

Frequently Asked Questions

What does Parabilis Medicines' $1.1 billion cash position mean for shareholders?

The company said the balance of cash, cash equivalents and marketable securities funds operations into 2030, which covers the planned PEDESTAL Phase 3 trial and the FAP, colorectal and liver programs. That runway reduces near-term dilution risk relative to a biotech that must raise during a pivotal trial. It does not guarantee trial success, and spending could rise if Parabilis adds indications or enrolls faster than planned.

Why did Parabilis's net loss widen in the third quarter of 2026?

The company attributed the $11.0 million increase in net loss to higher operating costs. Research and development rose $17.4 million on zolucatetide clinical development and hiring, while general and administrative costs rose $4.7 million on employee costs and public-company expenses. Partly offsetting that, interest income climbed to $10.4 million from $0.7 million as the securities portfolio grew after the company's listing.

What is zolucatetide and which diseases is it being tested in?

Parabilis describes zolucatetide as the first and only direct inhibitor of the β-catenin:TCF interaction in the Wnt/β-catenin pathway. It is in clinical testing for desmoid tumors, familial adenomatous polyposis, adamantinomatous craniopharyngioma, hepatocellular carcinoma and, under a collaboration with Revolution Medicines, RAS G12D mutant microsatellite stable metastatic colorectal cancer.

Bottom Line

Parabilis ended the quarter with $1.1 billion and FDA-aligned Phase 3 design, shifting the zolucatetide story from dose-finding to execution risk.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.